Posted by Michael Wonder on 10 Sep 2025
FDA grants fast track designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis
9 September 2025 - NS Pharma, a subsidiary of Nippon Shinyaku, announced today that the US FDA has granted fast track designation to NS-229, which is being developed for the treatment of the rare disease eosinophilic granulomatosis with polyangiitis.
NS-229 is being investigated as a selective Janus kinase 1 inhibitor to help regulate immune cell function and prevent the immune system from causing tissue damage.
